Molecular Cancer Therapeutics
The Cancer Drug Development Journal: From Concept to Clinic
December 2011 • Volume 10 • Number 12

Contents

Highlights of This Issue 2213

REVIEW

2215 New Insights into Molecular Mechanisms of Sunitinib-Associated Side Effects
Guadalupe Aparicio-Gallego, Moisés Blanco, Angélica Figueroa, Rosario García-Campelo, Manuel Valladares-Ayerbes, Enrique Grande-Pulido, and Luis Antón-Aparicio

THERAPEUTIC DISCOVERY

2224 Artesunate Induces Oxidative DNA Damage, Sustained DNA Double-Strand Breaks, and the ATM/ATR Damage Response in Cancer Cells
Nicole Berdelle, Teodora Nikolova, Steve Quiros, Thomas Efferth, and Bernd Kaina

2234 Direct Role of Adiponectin and Adiponectin Receptors in Endometrial Cancer: In Vitro and Ex Vivo Studies in Humans
Hyun-Seuk Moon, John P. Chamberland, Konstantinos Aronis, Sofia Tseleni-Balafouta, and Christos S. Mantzoros

2244 Inhibition of SAPK2/p38 Enhances Sensitivity to mTORC1 Inhibition by Blocking IRES-Mediated Translation Initiation in Glioblastoma
Cheri Cloninger, Andrew Bernath, Tariq Bashir, Brent Holmes, Nicholas Artinian, Teresa Ruegg, Lauren Anderson, Janine Masri, Alan Lichtenstein, and Joseph Gera

2257 Acquisition of Resistance toward HYD1 Correlates with a Reduction in Cleaved α4 Integrin Expression and a Compromised CAM-DR Phenotype
Michael F. Emmons, Anthony W. Gebhard, Rajesh R. Nair, Rachid Baz, Mark L. McLaughlin, Anne E. Cress, and Lori A. Hazlehurst

PRECLINICAL DEVELOPMENT

2267 Characterization of the Cellular and Antitumor Effects of MPI-0479605, a Small-Molecule Inhibitor of the Mitotic Kinase Mps1

2276 Integrin α6high Cell Population Functions as an Initiator in Tumorigenesis and Relapse of Human Liposarcoma
Lu Wang, Lingxian Wang, Yanhong Gu, Yongqian Shu, Yan Shen, and Qiang Xu

2287 Micelle-Encapsulated Thiostrepton as an Effective Nanomedicine for Inhibiting Tumor Growth and for Suppressing FOXM1 in Human Xenografts
Ming Wang and Andrei L. Gartel

2298 Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

The Cancer Drug Development Journal: From Concept to Clinic www.aacrijournals.org

Downloaded from mct.aacrjournals.org on January 14, 2018. © 2011 American Association for Cancer Research.
Reduced Expression of the Androgen Receptor by Third Generation of Antisense Shows Antitumor Activity in Models of Prostate Cancer

Yixian Zhang, Stephen Castaneda, Melissa Dumble, Maoliang Wang, Mary Mileski, Zhongxing Qu, Steven Kim, Victoria Shi, Patricia Kraft, Ying Gao, Jenny Pak, Puja Sapra, Raj Bandaru, Hong Zhao, Robert L. Vessella, Ivan D. Horak, and Lee M. Greenberger

The Clinically Active PARP Inhibitor AG014699 Ameliorates Cardiotoxicity but Does Not Enhance the Efficacy of Doxorubicin, despite Improving Tumor Perfusion and Radiation Response in Mice


Differential Expression of Uridine Phosphorylase in Tumors Contributes to an Improved Fluoropyrimidine Therapeutic Activity

Deliang Cao, Amy Ziembia, James McCabe, Ruilan Yan, Laxiang Wan, Bradford Kim, Michael Gach, Stuart Flynn, and Giuseppe Pizzorno

The Bcl-2/Bcl-Xl/Bcl-w Inhibitor, Navitoclax, Enhances the Activity of Chemotherapeutic Agents In Vitro and In Vivo


Dual Inhibition of Tumor Energy Pathway by 2-Deoxyglucose and Metformin Is Effective against a Broad Spectrum of Preclinical Cancer Models

Jae-Ho Cheong, Eun Sung Park, Jiyoung Liang, Jennifer B. Dennison, Dimitra Tsavachidou, Catherine Nguyen-Charles, Kwai Wa Cheng, Hassan Hall, Dong Zhang, Yiling Lu, Murali Ravoori, Vikas Kundra, Jaffer Ajani, Ju-Soong Lee, Waun Ki Hong, and Gordon B. Mills

Vitamin E δ-Tocotrienol Augments the Antitumor Activity of Gemcitabine and Suppresses Constitutive NF-κB Activation in Pancreatic Cancer

Kazim Husain, Rony A. Francois, Teruo Yamauchi, Marta Perez, Said M. Sebti, and Mokenge P. Malafa

MOLECULAR MEDICINE IN PRACTICE

GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway

ABOUT THE COVER

Human lung microvascular cells cocultured with human diploid fibroblasts form extensive networks of tubules in response to VEGF that can be visualized by immunostaining for CD31, an endothelial cell marker. In the presence of cabozantinib (XL184), a small-molecule kinase inhibitor with potent activity toward MET and VEGF receptor 2, it was found that tubule formation was inhibited in the absence of cytotoxicity. Similarly, cabozantinib inhibited tubule formation in response to conditioned media derived from tumor cell cultures, suggesting that secreted tumor cell-derived proangiogenic growth factors are unable to circumvent inhibition of tubule formation by cabozantinib. For details, see article by Yakes and colleagues on page 2298.
# Molecular Cancer Therapeutics

10 (12)


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: <a href="http://mct.aacrjournals.org/content/10/12">http://mct.aacrjournals.org/content/10/12</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reprints and Subscriptions</td>
<td>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</td>
</tr>
<tr>
<td>Permissions</td>
<td>To request permission to re-use all or part of this article, use this link <a href="http://mct.aacrjournals.org/content/10/12">http://mct.aacrjournals.org/content/10/12</a>. Click on &quot;Request Permissions&quot; which will take you to the Copyright Clearance Center's (CCC) Rightslink site.</td>
</tr>
</tbody>
</table>